Lovastatin suppresses bacterial therapy-induced neutrophil recruitment to the tumor by promoting neutrophil apoptosis

Lovastatin is a statin produced by Monascus purpureous-fermented pu-erh tea, which is used in the treatment of cardiovascular diseases and prostate cancer. Bacteria-mediated cancer immunotherapy (BCI), which is an effective antitumor strategy compared with conventional immunotherapies, targets neutr...

Full description

Bibliographic Details
Main Authors: Hong Zhang, Shaoting Sang, Huimin Xu, Linghua Piao, Xiande Liu
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:Journal of Functional Foods
Subjects:
ERK
AKT
Online Access:http://www.sciencedirect.com/science/article/pii/S175646462100342X
Description
Summary:Lovastatin is a statin produced by Monascus purpureous-fermented pu-erh tea, which is used in the treatment of cardiovascular diseases and prostate cancer. Bacteria-mediated cancer immunotherapy (BCI), which is an effective antitumor strategy compared with conventional immunotherapies, targets neutrophil infiltration associated with tumor recurrence and metastasis. In mouse colon cancer models, combination treatment with lovastatin and BCI suppressed tumor progression by extending the survival of tumor-colonizing bacteria. We used zebrafish live imaging to show that lovastatin decreases the recruitment of neutrophils to the inflammatory site by inducing neutrophil apoptosis via phosphorylation of ERK and AKT. The present findings suggest that the combination of BCI with lovastatin or fermented pu-erh tea is an effective approach compared with conventional cancer immunotherapy.
ISSN:1756-4646